ADCs undergoing clinical evaluation for the treatment of hematologic malignancies
| Target . | Conjugate . | B-cell . | T-cell NHL . | Myeloid leukemia . | Hodgkin lymphoma . | |||
|---|---|---|---|---|---|---|---|---|
| NHL . | CLL . | MM . | ALL . | |||||
| CD3 | Diphtheria toxin A | X | ||||||
| CD19 | DM4 | X | X | X | ||||
| CD22 | Calicheamicin, MMAE, PE38 | X | X | X | ||||
| CD30 | MMAE | X | FDA approved* | FDA approved* | ||||
| CD33 | DM4, gelonin | X | ||||||
| CD37 | DM1 | X | X | X | X | |||
| CD56 | DM1 | X | ||||||
| CD74 | Doxorubicin | X | ||||||
| CD79 | MMAE | X | ||||||
| CD138 | DM4 | X | X | X | X | |||
| Target . | Conjugate . | B-cell . | T-cell NHL . | Myeloid leukemia . | Hodgkin lymphoma . | |||
|---|---|---|---|---|---|---|---|---|
| NHL . | CLL . | MM . | ALL . | |||||
| CD3 | Diphtheria toxin A | X | ||||||
| CD19 | DM4 | X | X | X | ||||
| CD22 | Calicheamicin, MMAE, PE38 | X | X | X | ||||
| CD30 | MMAE | X | FDA approved* | FDA approved* | ||||
| CD33 | DM4, gelonin | X | ||||||
| CD37 | DM1 | X | X | X | X | |||
| CD56 | DM1 | X | ||||||
| CD74 | Doxorubicin | X | ||||||
| CD79 | MMAE | X | ||||||
| CD138 | DM4 | X | X | X | X | |||
X's indicate target expression.
ALL, acute lymphoblastic leukemia; MM, multiple myeloma; MMAE, monomethylauristatin E.
At this time, only brentuximab vedotin is approved by the FDA.